Clinical impact of brachyury expression in Ewing sarcoma patients
Carregando...
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2021
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER URBAN & PARTNER SP Z O O
Autores
ABRAHAO-MACHADO, Lucas Faria
PINTO, Filipe
ANTUNES, Bruno
VOLC, Sahlua
BOLDRINI, Erica
REIS, Rui M.
Citação
ADVANCES IN MEDICAL SCIENCES, v.66, n.2, p.321-325, 2021
Resumo
Purpose: The T-box transcription factor brachyury has been demonstrated as a prognostic factor in a variety of cancer types and considered a novel oncotarget in solid tumors. Brachyury acts as a regulator of the epithelialmesenchymal transition (EMT) process, leading to more aggressive behavior and poorer prognosis. However, recent literature evidence suggests a tumor suppressor role in other neoplasms. In the present study, we aimed to study brachyury expression and its prognostic impact in Ewing sarcoma, an aggressive neoplasm of young individuals. Methods: We analyzed the expression of brachyury by immunohistochemistry in a series of 96 Ewing sarcomas in a tissue microarray and investigated the association of the protein expression with the clinical parameters and overall survival. Results: More than half of the cases (51%, n = 49) depicted positive nuclear brachyury expression, while a lack of expression was observed in 49% (n = 47) of cases. Nuclear brachyury staining was significantly associated with non-white ethnicity (p = 0.04) and axial localization (p = 0.025). Importantly, lack of brachyury expression was significantly associated with lower overall survival in multivariate analyses (hazard ratio - HR: 2.227, p = 0.008). Conclusions: Our findings indicate, that brachyury is an independent prognostic biomarker in Ewing sarcoma, which might suggest a tumor suppressor role and which yet to be fully elucidated.
Palavras-chave
Brachyury, Ewing sarcoma, Biomarkers, Prognosis, Tumor suppressor
Referências
- Abrahao-Machado LF, 2018, BIOMARK MED, V12, P35, DOI 10.2217/bmm-2017-0152
- Brunetto AL, 2015, PEDIATR BLOOD CANCER, V62, P1747, DOI 10.1002/pbc.25562
- Cash T, 2016, PEDIATR BLOOD CANCER, V63, P1771, DOI 10.1002/pbc.26096
- Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7
- DE Alava E, 2013, EWING SARCOMA WHO CL, P306
- Fernando RI, 2010, J CLIN INVEST, V120, P533, DOI 10.1172/JCI38379
- Gaspar N, 2015, J CLIN ONCOL, V33, P3036, DOI 10.1200/JCO.2014.59.5256
- Hamilton DH, 2017, CELLS TISSUES ORGANS, V203, P128, DOI 10.1159/000446495
- Hamilton DH, 2013, ONCOTARGET, V4, P1777, DOI 10.18632/oncotarget.1295
- Hamilton SN, 2017, AM J CLIN ONCOL-CANC, V40, P423, DOI 10.1097/COC.0000000000000176
- Haro A, 2013, ANN SURG ONCOL, V20, pS509, DOI 10.1245/s10434-013-2914-9
- Kim SK, 2016, HUM PATHOL, V55, P91, DOI 10.1016/j.humpath.2016.05.008
- Miettinen M, 2015, AM J SURG PATHOL, V39, P1305, DOI 10.1097/PAS.0000000000000462
- Palena C, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju054
- Pinto F, 2018, ANDROLOGY-US, V6, P597, DOI 10.1111/andr.12495
- Pinto F, 2020, NEUROTHERAPEUTICS, V17, P2015, DOI 10.1007/s13311-020-00911-9
- Pinto F, 2020, J PATHOL, V251, P87, DOI 10.1002/path.5419
- Pinto F, 2016, GASTRIC CANCER, V19, P651, DOI 10.1007/s10120-015-0505-0
- Pinto F, 2014, CLIN CANCER RES, V20, P4949, DOI 10.1158/1078-0432.CCR-14-0421
- Robinson H, 2020, TRENDS CANCER, V6, P271, DOI 10.1016/j.trecan.2020.01.014
- Rodriguez-Galindo C, 2007, CANCER-AM CANCER SOC, V110, P375, DOI 10.1002/cncr.22821
- Roselli M, 2012, CLIN CANCER RES, V18, P3868, DOI 10.1158/1078-0432.CCR-11-3211
- Sannino G, 2017, CANCER RES, V77, P4556, DOI 10.1158/0008-5472.CAN-17-0032
- Sbaraglia M, 2020, VIRCHOWS ARCH, V476, P109, DOI 10.1007/s00428-019-02720-8
- Tirabosco R, 2008, AM J SURG PATHOL, V32, P572, DOI 10.1097/PAS.0b013e31815b693a
- Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969
- WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0
- Wold L.E., 2005, AM REGIST PATHOL